Cytel Inc. has launched East Bayes®, an enhanced web-based extension of the East® platform that enables adoption of the most computationally intensive Bayesian clinical trial designs – without the need for powerful on-site computers.

LabVantage Solutions, Inc., today announced that the 8.6 edition of its flagship LIMS has been designed and tested to optimum cybersecurity standards.

LabVantage Solutions, Inc., today announced the launch of LabVantage Analytics, a full-featured, self-service advanced analytics solution that lets users easily explore, analyze, and visualize LIMS, enterprise, and external data to gain actionable business insights.

LabVantage Solutions, Inc., today announced it has added validation to a number of its subscription-based LIMS.

Aptamer Group has announced the extension of their current agreement with AstraZeneca. This agreement will further the existing collaboration to evaluate the potential of using Optimer-based strategies to target renal cells and explore the feasibility of developing next-generation drug delivery vehicles, Optimer-drug conjugates.

Dotmatics Ltd, has announced that it has entered a licensing agreement with Compugen. The multi-year agreement will provide Compugen scientists based at the Company’s R&D facility in Israel with a single information management platform.

ViaCyte, Inc., and W. L. Gore & Associates, Inc., have announced an expanded joint development agreement covering the development and use of Gore materials and device capabilities to further optimize ViaCyte's product candidates for the treatment of diabetes.

Sygnature Discovery, an integrated drug discovery and non-clinical solutions provider, has begun expanding into new laboratories at Bruntwood SciTech’s Alderley Park, Cheshire, adding Chemistry and Biology expertise to its DMPK and Translational Oncology teams already present on the site.

As the world continues to seek solutions in response to the coronavirus pandemic, Beckman Coulter Life Sciences announces it is the first United States distributor of the Genedrive® 96 SARS-CoV-2 kit.

Newcastle-based human stem cell model specialists, Newcells Biotech, have secured a total of £5.25m worth of funding to accelerate their growth plans in the international life sciences market.